Literature DB >> 10734027

Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

M Persico1, E Persico, R Suozzo, S Conte, M De Seta, L Coppola, B Palmentieri, F C Sasso, R Torella.   

Abstract

BACKGROUND & AIMS: Some patients with serum hepatitis C virus (HCV) have persistently normal aminotransferase (ALT) levels and are affected by cirrhosis. This study prospectively evaluated progression of the disease in a group of anti-HCV-positive patients with persistently normal ALT levels.
METHODS: Thirty-seven subjects were studied. Each subject underwent liver biopsy at baseline and after 5 years of follow-up. At baseline, serum samples were tested for genotypes and HCV RNA load. ALT levels and serum HCV RNA were tested every other month and every 6 months, respectively. Patients with increased ALT were discharged from the study and treated with IFN. Five years after the end of IFN therapy, a liver biopsy was performed.
RESULTS: Liver biopsy at baseline showed chronic hepatitis in 34 patients and normal histology in 3 patients, 2 of whom were negative for HCV RNA and 1 positive. HCV genotypes were distributed as follows: 2a, 56%; 1b, 41%; and 1a, 3%. At the end of 7-year follow-up, 73% of the patients still had normal ALT values. Liver histology after 5 years was comparable to that observed at entry to study.
CONCLUSIONS: Most patients with persistently normal ALT serum levels have very mild chronic hepatitis. However, healthy anti-HCV-positive subjects exist. In patients with HCV-related chronic hepatitis associated with persistently normal ALT levels, the grade of disease activity does not increase over years and progression to cirrhosis is slow or absent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10734027     DOI: 10.1016/s0016-5085(00)70145-4

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  27 in total

1.  Increased hepatitis C virus (HCV)-specific CD4+CD25+ regulatory T lymphocytes and reduced HCV-specific CD4+ T cell response in HCV-infected patients with normal versus abnormal alanine aminotransferase levels.

Authors:  F Bolacchi; A Sinistro; C Ciaprini; F Demin; M Capozzi; F C Carducci; C M J Drapeau; G Rocchi; A Bergamini
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

2.  Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients.

Authors:  M G Rumi; F De Filippi; C La Vecchia; M F Donato; S Gallus; E Del Ninno; M Colombo
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

Review 3.  Hepatitis C virus markers in infection by hepatitis C virus: In the era of directly acting antivirals.

Authors:  Nicola Coppola; Mariantonietta Pisaturo; Rosa Zampino; Margherita Macera; Caterina Sagnelli; Evangelista Sagnelli
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

4.  Efficacy of pegylated interferon plus ribavirin combination therapy for hepatitis C patients with normal ALT levels: a matched case-control study.

Authors:  Naoki Hiramatsu; Yuko Inoue; Tsugiko Oze; Nao Kurashige; Takayuki Yakushijin; Kiyoshi Mochizuki; Takuya Miyagi; Tomohide Tatsumi; Shinichi Kiso; Tatsuya Kanto; Akinori Kasahara; Tetsuo Takehara; Masahide Oshita; Eiji Mita; Hideki Hagiwara; Yoshiaki Inui; Kazuhiro Katayama; Shinji Tamura; Harumasa Yoshihara; Yasuharu Imai; Norio Hayashi
Journal:  J Gastroenterol       Date:  2011-08-20       Impact factor: 7.527

5.  Detection of Occult Hepatitis C Virus Infection in Patients Who Achieved a Sustained Virologic Response to Direct-Acting Antiviral Agents for Recurrent Infection After Liver Transplantation.

Authors:  Sandra Elmasry; Sanya Wadhwa; Bo-Ram Bang; Linda Cook; Shefali Chopra; Gary Kanel; Brian Kim; Tammy Harper; Zongdi Feng; Keith R Jerome; Jeffrey A Kahn; Takeshi Saito
Journal:  Gastroenterology       Date:  2016-11-09       Impact factor: 22.682

6.  The management of chronic viral hepatitis: A Canadian consensus conference 2004.

Authors:  Morris Sherman; Vincent Bain; Jean-Pierre Villeneuve; Robert P Myers; Curtis Cooper; Steven Martin; Catherine Lowe
Journal:  Can J Infect Dis Med Microbiol       Date:  2004-11       Impact factor: 2.471

7.  Clinicopathological features and genotype distribution in patients with hepatitis C virus chronic liver disease.

Authors:  Rachel Abraham; Banumathi Ramakrishna; Avinash Balekuduru; Hubert Darius J Daniel; Priya Abraham; C Eapen Eapen; George Kurian
Journal:  Indian J Gastroenterol       Date:  2009-08-21

8.  Combination treatment of IFNalpha2b and ribavirin in patients with chronic hepatitis C and persistently normal ALTs.

Authors:  Andreas Erhardt; Ulla Behlen-Wilm; Ortwin Adams; Andreas Donner; Tobias Heintges; Dieter Häussinger
Journal:  Dig Dis Sci       Date:  2003-05       Impact factor: 3.199

9.  Outcomes of interferon alpha and ribavirin treatment for chronic hepatitis C in patients with normal serum aminotransaminases.

Authors:  C-K Hui; A Monto; T Belaye; E Lau; T L Wright
Journal:  Gut       Date:  2003-11       Impact factor: 23.059

Review 10.  The history of the "natural history" of hepatitis C (1968-2009).

Authors:  Leonard B Seeff
Journal:  Liver Int       Date:  2009-01       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.